Author Topic: Alnylam Patisiran Trial for Hereditay ATTR with FAP  (Read 4089 times)

georgeturner

  • ***
  • Posts: 126
  • Reason for joining: Patient Familial ATTR amyloidosis
  • Diagnosed: 13 May 2014
Alnylam Patisiran Trial for Hereditay ATTR with FAP
« on: April 20, 2016, 08:42:58 pm »
Complete 18-Month Data from Ongoing Phase 2 OLE Study with Patisiran in Development for the Treatment of Hereditary TTR-Mediated Amyloidosis with Polyneuropathy (hATTR-PN).

http://www.alnylam.com/capella/presentations/complete-18-month-ph-2-ole-data-from-patisiran/
Slainte Mhath,
George

Roger Curlett

  • *
  • Posts: 5
  • Reason for joining: hereditary ATTR amyloidosis patient
  • Diagnosed: March 2015
Re: Alnylam Patisiran Trial for Hereditay ATTR with FAP
« Reply #1 on: April 24, 2016, 09:57:09 pm »
Cheers George, hopefully we'll all have access to this drug once it's available post trials.

georgeturner

  • ***
  • Posts: 126
  • Reason for joining: Patient Familial ATTR amyloidosis
  • Diagnosed: 13 May 2014
Re: Alnylam Patisiran Trial for Hereditay ATTR with FAP
« Reply #2 on: April 25, 2016, 10:09:48 am »
Roger,

With the trials of ALNYLAM's Patisiran and Revusiran along IONIS TTR RX all showing promising results, it's looking much more hopeful for ATTR patients. It takes a lot of time, but let's hope they are approved and become available soon.
Slainte Mhath,
George